{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import random\n",
    "import re\n",
    "import sys\n",
    "import time\n",
    "\n",
    "import pandas as pd\n",
    "from agents import clinical_agent\n",
    "from agents.planning_agent import decomposition\n",
    "from openai import OpenAI\n",
    "from sklearn.metrics import (\n",
    "    accuracy_score,\n",
    "    auc,\n",
    "    f1_score,\n",
    "    log_loss,\n",
    "    precision_recall_curve,\n",
    "    precision_score,\n",
    "    recall_score,\n",
    "    roc_auc_score,\n",
    ")\n",
    "from tqdm import tqdm\n",
    "\n",
    "from core.utils import LOGGER, llm_request\n",
    "from core.constants import LLMConstants\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "sys.path.append(os.getcwd())\n",
    "client = OpenAI(api_key=LLMConstants.OPENAI_API_KEY)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def solve_problem(user_problem):\n",
    "    agent_tools = [\n",
    "        {\n",
    "            \"type\": \"function\",\n",
    "            \"function\": {\n",
    "                \"name\": \"safety_agent\",\n",
    "                \"description\": \"To understand the safety of the drug, including toxicity and side effects, consult the Safety Agent for safety information. Given drug name, return the safety information of the drug, e.g. drug introduction, toxicity and side effects etc.\",\n",
    "                \"parameters\": {\n",
    "                    \"type\": \"object\",\n",
    "                    \"properties\": {\n",
    "                        \"drug_name\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The drug name\",\n",
    "                        }\n",
    "                    },\n",
    "                    \"required\": [\"drug_name\"],\n",
    "                },\n",
    "            },\n",
    "        },\n",
    "        {\n",
    "            \"type\": \"function\",\n",
    "            \"function\": {\n",
    "                \"name\": \"efficiency_agent\",\n",
    "                \"description\": \"To assess the drug's efficiency against the diseases, ask the efficiency Agent for information regarding the drug's effectiveness on the disease. Given drug name and disease name, return the drug introduction, disease introduction, and the path between drug and disease in the hetionet knowledge graph etc.\",\n",
    "                \"parameters\": {\n",
    "                    \"type\": \"object\",\n",
    "                    \"properties\": {\n",
    "                        \"drug_name\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The drug name\",\n",
    "                        },\n",
    "                        \"disease_name\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The disease name\",\n",
    "                        },\n",
    "                    },\n",
    "                    \"required\": [\"drug_name\", \"disease_name\"],\n",
    "                },\n",
    "            },\n",
    "        },\n",
    "        {\n",
    "            \"type\": \"function\",\n",
    "            \"function\": {\n",
    "                \"name\": \"enrollment_agent\",\n",
    "                \"description\": \"To determine if the clinical trial's eligibility criteria facilitate easy enrollment with enough patients. Given eligibility criteria, return the clinical trial will be poor enrollment, good enrollment, or excellent enrollment.\",\n",
    "                \"parameters\": {\n",
    "                    \"type\": \"object\",\n",
    "                    \"properties\": {\n",
    "                        \"eligibility_criteria\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"eligibility criteria, contains including criteria and excluding criteria\",\n",
    "                        }\n",
    "                    },\n",
    "                    \"required\": [\"eligibility_criteria\"],\n",
    "                },\n",
    "            },\n",
    "        },\n",
    "        {\n",
    "            \"type\": \"function\",\n",
    "            \"function\": {\n",
    "                \"name\": \"graph_reasoning_agent\",\n",
    "                \"description\": \"The Graph Reasoning Agent is designed to interpret and respond to requests by analyzing graph structures. The agent loads the specified graph, processes the relationships or paths between the nodes, and delivers a response aligned with the user's instruction. Ideal for tasks involving graph-based data reasoning and exploration.\",\n",
    "                \"parameters\": {\n",
    "                    \"type\": \"object\",\n",
    "                    \"properties\": {\n",
    "                        \"keyword_1\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The first keyword indicating a node in the graph\",\n",
    "                        },\n",
    "                        \"keyword_2\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The second keyword indicating a node in the graph\",\n",
    "                        },\n",
    "                        \"user_instruction\": {\n",
    "                            \"type\": \"string\",\n",
    "                            \"description\": \"The request to be answered\",\n",
    "                        },\n",
    "                    },\n",
    "                    \"required\": [\n",
    "                        \"keyword_1\",\n",
    "                        \"keyword_2\",\n",
    "                        \"user_instruction\",\n",
    "                    ],\n",
    "                },\n",
    "            },\n",
    "        },\n",
    "    ]\n",
    "\n",
    "\n",
    "    LOGGER.log_with_depth(f\"User problem:\\n {user_problem}\", depth=0)\n",
    "\n",
    "    ##################\n",
    "    ###  PLANNING  ###\n",
    "    ##################\n",
    "    LOGGER.log_with_depth(f\"Planing...\", depth=0)\n",
    "    time.sleep(2)\n",
    "    LOGGER.log_with_depth(f\"[Thought] Least to Most Reasoning: Decompose the original user problem\", depth=0)\n",
    "    decomposed_resp = decomposition(user_problem, agent_tools)\n",
    "\n",
    "    subproblems = re.findall(r\"<subproblem>(.*?)</subproblem>\", decomposed_resp)\n",
    "    subproblems = [subproblem.strip() for subproblem in subproblems]\n",
    "\n",
    "    for idx, subproblem in enumerate(subproblems):\n",
    "        LOGGER.log_with_depth(f\"<subproblem>{subproblem}</subproblem>\", depth=0)\n",
    "\n",
    "    problem_results = []\n",
    "\n",
    "    clinicalAgent = clinical_agent.ClinicalAgent(user_problem, depth=1)\n",
    "\n",
    "    LOGGER.log_with_depth(f\"[Action] Solve each subproblem...\", depth=0)\n",
    "    for sub_problem in subproblems:\n",
    "        LOGGER.log_with_depth(f\"Solving...\", depth=0)\n",
    "        response = clinicalAgent.request(f\"The original user problem is: {user_problem}\\nNow, please you solve this problem: {sub_problem}\")\n",
    "\n",
    "        LOGGER.log_with_depth(f\"<solution>{response}</solution>\", depth=0)\n",
    "        problem_results.append(response)\n",
    "        \n",
    "    problem_results = '\\n'.join(problem_results)\n",
    "    \n",
    "    messages = []\n",
    "\n",
    "    LOGGER.log_with_depth(\"Thinking...\")\n",
    "    time.sleep(2)\n",
    "    LOGGER.log_with_depth(\"[Action] Requesting the final result from the Reasoning Agent...\", depth=0)\n",
    "\n",
    "    fewshot_examples = open(\"few_shot.txt\", \"r\").read()\n",
    "    system_prompt = f''' \n",
    "        You are an expert in clinical trials. Based on your own knowledge and the sub-problems have solved, please solve the user's problem and provide the reason.\n",
    "        First, Analysis the user's problem.\n",
    "        Second, present the final result of the user's problem in <final_result></final_result>, for a binary problem, it is a value between 0 to 1. You must include the exact probability within the <final_result></final_result> tags, e.g., 'The failure rate of the clinical trial is <final_result>0.8</final_result>.'\n",
    "        Third, explain the reason step by step.\n",
    "        Noted, you must include the exact probability within the <final_result></final_result> tags.\n",
    "\n",
    "        The following examples are essential for your understanding, offering significant learning opportunities. By analyzing these examples, including sub-problems and labels, you will learn how to make accurate predictions.\n",
    "        Each example is within the <example></example> tags.\n",
    "        Examples:\n",
    "        {fewshot_examples}\n",
    "    '''\n",
    "    \n",
    "    \n",
    "    messages.append({ \"role\": \"system\", \"content\": system_prompt})\n",
    "    messages.append({ \"role\": \"user\", \"content\": f\"The original user problem is: {user_problem}\"})\n",
    "    messages.append({ \"role\": \"user\", \"content\": f\"The subproblems have solved are: {problem_results}\"})\n",
    "    messages.append({ \"role\": \"user\", \"content\": \"Please solve the user's problem and provide the reason.\"})\n",
    "\n",
    "    final_results = llm_request(messages, model='gpt-4-turbo')\n",
    "    LOGGER.log_with_depth(final_results.choices[0].message.content, depth=0)\n",
    "    LOGGER.log_with_depth(\"\\n======================    END   ================\\n\\n\", depth=0)\n",
    "\n",
    "    return problem_results, final_results.choices[0].message.content\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "cwd_path = os.getcwd()\n",
    "trial_df = pd.read_csv(f\"{cwd_path}/agents/tools/risk_model/data/trial_success.csv\", sep='\\t')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>criteria</th>\n",
       "      <th>drugs</th>\n",
       "      <th>diseases</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>NCT00040404</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\nPatients will be in...</td>\n",
       "      <td>cep-1347 10mg;cep1347 25mg;cep-1347 50mg</td>\n",
       "      <td>parkinson disease</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>930</th>\n",
       "      <td>NCT00099268</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  -  Clinical diagn...</td>\n",
       "      <td>carbidopa/levodopa/entacapone;immediate releas...</td>\n",
       "      <td>parkinson's disease</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1011</th>\n",
       "      <td>NCT00105508</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  -  The subject is...</td>\n",
       "      <td>sarizotan;placebo</td>\n",
       "      <td>parkinson's disease;dyskinesia</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1269</th>\n",
       "      <td>NCT00125567</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  -  Idiopathic Par...</td>\n",
       "      <td>stalevo (levodopa/carbidopa/entacapone);levodo...</td>\n",
       "      <td>idiopathic parkinson's disease</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1374</th>\n",
       "      <td>NCT00134966</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  -  Aged 30 to 80 ...</td>\n",
       "      <td>capsules containing: carbidopa (25 mg), levodo...</td>\n",
       "      <td>parkinson's disease</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22599</th>\n",
       "      <td>NCT03257046</td>\n",
       "      <td>Major Inclusion Criteria:\\r\\n\\r\\n  -  Clinical...</td>\n",
       "      <td>iti-214</td>\n",
       "      <td>parkinson disease</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22756</th>\n",
       "      <td>NCT03368170</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  1. Male or female...</td>\n",
       "      <td>mesdopetam (irl790)</td>\n",
       "      <td>parkinson disease</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22894</th>\n",
       "      <td>NCT03482882</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  1. Can understand...</td>\n",
       "      <td>pimavanserin</td>\n",
       "      <td>treatment of depression in adults with parkins...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22927</th>\n",
       "      <td>NCT03531060</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  1. Male or female...</td>\n",
       "      <td>irl790;placebo</td>\n",
       "      <td>parkinson disease</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22960</th>\n",
       "      <td>NCT03576638</td>\n",
       "      <td>Inclusion Criteria:\\r\\n\\r\\n  1. diagnosis of P...</td>\n",
       "      <td>accordion pill carbidopa/levodopa;sinemet cr 2...</td>\n",
       "      <td>parkinson disease</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>241 rows Ã— 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             nctid                                           criteria  \\\n",
       "274    NCT00040404  Inclusion Criteria:\\r\\n\\r\\nPatients will be in...   \n",
       "930    NCT00099268  Inclusion Criteria:\\r\\n\\r\\n  -  Clinical diagn...   \n",
       "1011   NCT00105508  Inclusion Criteria:\\r\\n\\r\\n  -  The subject is...   \n",
       "1269   NCT00125567  Inclusion Criteria:\\r\\n\\r\\n  -  Idiopathic Par...   \n",
       "1374   NCT00134966  Inclusion Criteria:\\r\\n\\r\\n  -  Aged 30 to 80 ...   \n",
       "...            ...                                                ...   \n",
       "22599  NCT03257046  Major Inclusion Criteria:\\r\\n\\r\\n  -  Clinical...   \n",
       "22756  NCT03368170  Inclusion Criteria:\\r\\n\\r\\n  1. Male or female...   \n",
       "22894  NCT03482882  Inclusion Criteria:\\r\\n\\r\\n  1. Can understand...   \n",
       "22927  NCT03531060  Inclusion Criteria:\\r\\n\\r\\n  1. Male or female...   \n",
       "22960  NCT03576638  Inclusion Criteria:\\r\\n\\r\\n  1. diagnosis of P...   \n",
       "\n",
       "                                                   drugs  \\\n",
       "274             cep-1347 10mg;cep1347 25mg;cep-1347 50mg   \n",
       "930    carbidopa/levodopa/entacapone;immediate releas...   \n",
       "1011                                   sarizotan;placebo   \n",
       "1269   stalevo (levodopa/carbidopa/entacapone);levodo...   \n",
       "1374   capsules containing: carbidopa (25 mg), levodo...   \n",
       "...                                                  ...   \n",
       "22599                                            iti-214   \n",
       "22756                                mesdopetam (irl790)   \n",
       "22894                                       pimavanserin   \n",
       "22927                                     irl790;placebo   \n",
       "22960  accordion pill carbidopa/levodopa;sinemet cr 2...   \n",
       "\n",
       "                                                diseases  label  \n",
       "274                                    parkinson disease      0  \n",
       "930                                  parkinson's disease      0  \n",
       "1011                      parkinson's disease;dyskinesia      0  \n",
       "1269                      idiopathic parkinson's disease      1  \n",
       "1374                                 parkinson's disease      1  \n",
       "...                                                  ...    ...  \n",
       "22599                                  parkinson disease      1  \n",
       "22756                                  parkinson disease      0  \n",
       "22894  treatment of depression in adults with parkins...      1  \n",
       "22927                                  parkinson disease      1  \n",
       "22960                                  parkinson disease      1  \n",
       "\n",
       "[241 rows x 5 columns]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trial_df = trial_df[trial_df[\"diseases\"].str.contains(\"parkinson\")]\n",
    "trial_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/1 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Random Index: 90\n",
      "NCT ID: NCT00640159, Label: 0\n",
      "\n",
      "User problem:\n",
      " \n",
      "        #My problem#: <problem>I have designed a clinical trial and hope you can help me predict the probability of failure for this clinical trial.</problem>\n",
      "        #drugs#: <drug>zelapar</drug>\n",
      "        #diseases#: <disease>parkinson's disease</disease>\n",
      "        #criteria#: <criteria>Inclusion Criteria:\n",
      "\n",
      "  1. Idiopathic PD confirmed by at least two of the following signs: resting tremor,\n",
      "     bradykinesia, rigidity\n",
      "\n",
      "  2. Male or female outpatients\n",
      "\n",
      "  3. Age 30-90 years\n",
      "\n",
      "  4. Current use of levodopa and oral selegiline (5-10 mg /day), stable for at least 1\n",
      "     month and well tolerated\n",
      "\n",
      "  5. Positive treatment response to current anti-parkinsonian medications in the opinion\n",
      "     of the investigator\n",
      "\n",
      "  6. Acceptable contraception for females of child bearing potential\n",
      "\n",
      "  7. Willing and able to comply with study procedures.\n",
      "\n",
      "  8. Willing and able to give written informed consent prior to beginning any study\n",
      "     procedures.\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "  1. Atypical parkinsonism due to drugs, metabolic disorders, encephalitis, trauma, or\n",
      "     other neurodegenerative diseases.\n",
      "\n",
      "  2. Significant cognitive or psychiatric impairment which, in the opinion of the\n",
      "     investigator, would interfere with the ability to complete all the tests required in\n",
      "     the protocol.\n",
      "\n",
      "  3. Participation in another clinical drug trial within the previous four weeks.\n",
      "\n",
      "  4. Patients on any medications contraindicated with Zelapar (including\n",
      "     meperidine/Demerol, tramadol, methadone, propoxyphene, dextromethorphan, other\n",
      "     selegiline products)\n",
      "\n",
      "  5. Patients with a known hypersensitivity to any formulation of selegiline or any of\n",
      "     the inactive ingredients of Zelapar, or previous exposure to orally disintegrating\n",
      "     selegiline\n",
      "\n",
      "  6. History of melanoma\n",
      "\n",
      "  7. Unstable/uncontrolled medical problems\n",
      "\n",
      "  8. History of drug/alcohol abuse\n",
      "\n",
      "  9. Patients currently taking rasagiline</criteria>\n",
      "        \n",
      "Planing...\n",
      "[Thought] Least to Most Reasoning: Decompose the original user problem\n",
      "<subproblem>To understand the safety of the drug Zelapar, we need to consult the Safety Agent for information on its risks, such as toxicity and side effects.</subproblem>\n",
      "<subproblem>To evaluate the drug's efficiency against Parkinson's disease, it is essential to request information on Zelapar's effectiveness from the efficiency Agent. This includes obtaining details about its pharmacological aspects and its impact on the disease per the hetionet knowledge graph.</subproblem>\n",
      "<subproblem>We must assess the criteria's impact on enrollment by consulting the Enrollment Agent to determine if the eligibility criteria will facilitate easy enrollment with enough patients.</subproblem>\n",
      "[Action] Solve each subproblem...\n",
      "Solving...\n",
      "--------[Action] Function calling...\n",
      "--------\n",
      "--------Safety Agent...\n",
      "--------Planing...\n",
      "--------[Thought] Least to Most Reasoning: Decompose the original problem\n",
      "--------<subproblem>To assess the risk associated with the drug zelapar, we must use the \"get_drug_risk\" tool.</subproblem>\n",
      "--------<subproblem>To evaluate the risk associated with the disease Parkinson's disease, we must use the \"get_disease_risk\" tool.</subproblem>\n",
      "--------<subproblem>Provide insights into the safety of both the drug and the disease based on your expertise, without resorting to any external tools.</subproblem>\n",
      "--------[Action] Solve each subproblem...\n",
      "--------Solving...\n",
      "----------------[Action] Function calling...\n",
      "--------<solution><function>get_drug_risk</function><result>The historical failure rate of zelapar in clinical trials is 0.0.</result></solution>\n",
      "--------Solving...\n",
      "----------------[Action] Function calling...\n",
      "--------<solution><function>get_disease_risk</function><result>The historical failure rate of parkinson's disease in clinical trials is 0.3566.</result></solution>\n",
      "--------Solving...\n",
      "--------<solution>Based on the given historical failure rates, we can infer the following:\n",
      "\n",
      "1. **Drug Risk for Zelapar**: \n",
      "   - Zelapar shows a historical failure rate of 0.0 in clinical trials, indicating that it has not shown significant issues or risks in past trials. This suggests that it has been relatively safe and effective concerning trial outcomes, and there is low risk associated with its continued use in clinical studies.\n",
      "\n",
      "2. **Disease Risk for Parkinson's Disease**: \n",
      "   - The historical failure rate for Parkinson's disease is 0.3566. This indicates a moderate risk of failure in clinical trials specifically addressing this disease. This failure rate may be attributed to the inherent complexities of treating Parkinson's disease, which can involve varied patient responses to treatment, progression of the disease, and diverse disease pathology.\n",
      "\n",
      "### Insights:\n",
      "\n",
      "- **Synergy in the Specific Clinical Context**: Considering Zelapar has been used effectively with a failure rate of 0.0, when used for Parkinson's disease, it could still reflect challenges due to the nature of the disease itself. Management in clinical settings should thus focus on comprehensive monitoring of the trial population's progression regarding these variables.\n",
      "\n",
      "- **Rigorous Patient Selection**: The inclusion and exclusion criteria you have mentioned are designed to ensure that the trial participants are as homogenous and representative of an ideal patient population as possible, reducing variability and external factors that might affect outcomes.\n",
      "\n",
      "- **Risk Mitigation Strategies**: Employing rigorous monitoring standards, adaptive trial designs, and interim analyses could help navigate the moderate failure risk inherent in Parkinson's disease trials. Being prepared to adapt based on real-time data may reduce failure rates derived from disease-related factors.\n",
      "\n",
      "- **Comprehensive Evaluation**: While Zelapar's low historical failure rate appears promising, trials must still conduct comprehensive pharmacovigilance to capture any new or rare adverse effects, especially given the chronic and complex nature of Parkinson's disease affecting patient responses over time.\n",
      "\n",
      "Overall, while the drug itself presents a low risk, the inherent difficulty in treating Parkinson's disease suggests the need for robust trial protocols, close monitoring, and a potentially adaptable trial design to address unforeseen challenges and maximize the trial's likelihood of success.</solution>\n",
      "--------<function>safety_agent</function><result><function>get_drug_risk</function><result>The historical failure rate of zelapar in clinical trials is 0.0.</result>\n",
      "<function>get_disease_risk</function><result>The historical failure rate of parkinson's disease in clinical trials is 0.3566.</result>\n",
      "Based on the given historical failure rates, we can infer the following:\n",
      "\n",
      "1. **Drug Risk for Zelapar**: \n",
      "   - Zelapar shows a historical failure rate of 0.0 in clinical trials, indicating that it has not shown significant issues or risks in past trials. This suggests that it has been relatively safe and effective concerning trial outcomes, and there is low risk associated with its continued use in clinical studies.\n",
      "\n",
      "2. **Disease Risk for Parkinson's Disease**: \n",
      "   - The historical failure rate for Parkinson's disease is 0.3566. This indicates a moderate risk of failure in clinical trials specifically addressing this disease. This failure rate may be attributed to the inherent complexities of treating Parkinson's disease, which can involve varied patient responses to treatment, progression of the disease, and diverse disease pathology.\n",
      "\n",
      "### Insights:\n",
      "\n",
      "- **Synergy in the Specific Clinical Context**: Considering Zelapar has been used effectively with a failure rate of 0.0, when used for Parkinson's disease, it could still reflect challenges due to the nature of the disease itself. Management in clinical settings should thus focus on comprehensive monitoring of the trial population's progression regarding these variables.\n",
      "\n",
      "- **Rigorous Patient Selection**: The inclusion and exclusion criteria you have mentioned are designed to ensure that the trial participants are as homogenous and representative of an ideal patient population as possible, reducing variability and external factors that might affect outcomes.\n",
      "\n",
      "- **Risk Mitigation Strategies**: Employing rigorous monitoring standards, adaptive trial designs, and interim analyses could help navigate the moderate failure risk inherent in Parkinson's disease trials. Being prepared to adapt based on real-time data may reduce failure rates derived from disease-related factors.\n",
      "\n",
      "- **Comprehensive Evaluation**: While Zelapar's low historical failure rate appears promising, trials must still conduct comprehensive pharmacovigilance to capture any new or rare adverse effects, especially given the chronic and complex nature of Parkinson's disease affecting patient responses over time.\n",
      "\n",
      "Overall, while the drug itself presents a low risk, the inherent difficulty in treating Parkinson's disease suggests the need for robust trial protocols, close monitoring, and a potentially adaptable trial design to address unforeseen challenges and maximize the trial's likelihood of success.</result>\n",
      "<solution><function>safety_agent</function><result><function>get_drug_risk</function><result>The historical failure rate of zelapar in clinical trials is 0.0.</result>\n",
      "<function>get_disease_risk</function><result>The historical failure rate of parkinson's disease in clinical trials is 0.3566.</result>\n",
      "Based on the given historical failure rates, we can infer the following:\n",
      "\n",
      "1. **Drug Risk for Zelapar**: \n",
      "   - Zelapar shows a historical failure rate of 0.0 in clinical trials, indicating that it has not shown significant issues or risks in past trials. This suggests that it has been relatively safe and effective concerning trial outcomes, and there is low risk associated with its continued use in clinical studies.\n",
      "\n",
      "2. **Disease Risk for Parkinson's Disease**: \n",
      "   - The historical failure rate for Parkinson's disease is 0.3566. This indicates a moderate risk of failure in clinical trials specifically addressing this disease. This failure rate may be attributed to the inherent complexities of treating Parkinson's disease, which can involve varied patient responses to treatment, progression of the disease, and diverse disease pathology.\n",
      "\n",
      "### Insights:\n",
      "\n",
      "- **Synergy in the Specific Clinical Context**: Considering Zelapar has been used effectively with a failure rate of 0.0, when used for Parkinson's disease, it could still reflect challenges due to the nature of the disease itself. Management in clinical settings should thus focus on comprehensive monitoring of the trial population's progression regarding these variables.\n",
      "\n",
      "- **Rigorous Patient Selection**: The inclusion and exclusion criteria you have mentioned are designed to ensure that the trial participants are as homogenous and representative of an ideal patient population as possible, reducing variability and external factors that might affect outcomes.\n",
      "\n",
      "- **Risk Mitigation Strategies**: Employing rigorous monitoring standards, adaptive trial designs, and interim analyses could help navigate the moderate failure risk inherent in Parkinson's disease trials. Being prepared to adapt based on real-time data may reduce failure rates derived from disease-related factors.\n",
      "\n",
      "- **Comprehensive Evaluation**: While Zelapar's low historical failure rate appears promising, trials must still conduct comprehensive pharmacovigilance to capture any new or rare adverse effects, especially given the chronic and complex nature of Parkinson's disease affecting patient responses over time.\n",
      "\n",
      "Overall, while the drug itself presents a low risk, the inherent difficulty in treating Parkinson's disease suggests the need for robust trial protocols, close monitoring, and a potentially adaptable trial design to address unforeseen challenges and maximize the trial's likelihood of success.</result></solution>\n",
      "Solving...\n",
      "--------[Action] Function calling...\n",
      "--------\n",
      "--------efficiency Agent...\n",
      "--------Planing...\n",
      "--------[Thought] Least to Most Reasoning: Decompose the original problem\n",
      "--------<subproblem>To understand the drug's structure, obtaining the SMILES notation of the drug zelapar is necessary.</subproblem>\n",
      "--------<subproblem>Assessing the drug's effectiveness requires retrieving information from the DrugBank database for zelapar.</subproblem>\n",
      "--------<subproblem>To evaluate the drug's impact on Parkinson's disease, we must obtain the pathway linking zelapar to Parkinson's disease from the Hetionet Knowledge Graph by using the retrieval_hetionet tool.</subproblem>\n",
      "--------<subproblem>Offer insights on the drug zelapar and Parkinson's disease based on your expertise, without resorting to any external tools.</subproblem>\n",
      "--------[Action] Solve each subproblem...\n",
      "----------------[Action] Function calling...\n",
      "Name: zelapar and its synonyms not found\n",
      "Similary Name Matching...\n",
      "----------------Similar Name: zelapar -> mepatar, levenshtein distance: 3\n",
      "--------<solution><function>get_SMILES</function><result>[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C</result></solution>\n",
      "----------------[Action] Function calling...\n",
      "Name: zelapar and its synonyms not found\n",
      "Similary Name Matching...\n",
      "----------------Similar Name: zelapar -> mepatar, levenshtein distance: 3\n",
      "--------<solution><function>retrieval_drugbank</function><result> \n",
      "    <drug name>mepatar</drug name>,\n",
      "    <drug description>A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.</drug description>,\n",
      "    <drug pharmacology indication>Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including <i>Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae</i> (respiratory infections), and <i>Diplococcus pneumoniae</i>.</drug pharmacology indication>,\n",
      "    <drug absorption>Readily absorbed following oral administration.</drug absorption>,\n",
      "    <drug volume-of-distribution>nan</drug volume-of-distribution>,\n",
      "    <drug metabolism>nan</drug metabolism>,\n",
      "    <drug route-of-elimination>nan</drug route-of-elimination>,\n",
      "    <drug toxicity>Adverse effects may include stomach or bowel upsets and rarely allergic reactions. Very rarely severe headache and vision problems may be signs of dangerous intracranial hypertenion.</drug toxicity>\n",
      "    </result></solution>\n",
      "----------------[Action] Function calling...\n",
      "Name: zelapar and its synonyms not found\n",
      "Similary Name Matching...\n",
      "----------------Similar Name: zelapar -> cela3a, levenshtein distance: 3\n",
      "----------------Similar Name: parkinson's disease -> parkinson's disease, levenshtein distance: 0\n",
      "--------<solution><function>retrieval_hetionet</function><result>NONE</result></solution>\n",
      "--------<solution>Given the information about Zelapar (selegiline) and its application in the context of Parkinson's disease, here's an analysis that could help predict the probability of failure in your clinical trial:\n",
      "\n",
      "### Zelapar Overview:\n",
      "- **Active Ingredient:** Selegiline\n",
      "- **Primary Use:** Zelapar is primarily used as an adjunct therapy in the management of Parkinson's disease. It functions by selectively inhibiting the monoamine oxidase-B (MAO-B) enzyme, which is involved in the breakdown of dopamine in the brain, thereby increasing the level of dopamine available.\n",
      "- **Formulation:** Zelapar is unique as an orally disintegrating form of selegiline, allowing for better absorption and ease of administration.\n",
      "\n",
      "### Parkinson's Disease Context:\n",
      "- **Disease Characteristics:** Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, bradykinesia, rigidity, and non-motor symptoms.\n",
      "- **Current Therapies:** The standard treatment protocols often involve levodopa combined with carbidopa, MAO-B inhibitors like selegiline, dopamine agonists, and other adjunct therapies.\n",
      "\n",
      "### Clinical Trial Insights:\n",
      "- **Inclusion/Exclusion Criteria:** The trial's criteria are designed to filter out confounding variables that could interfere with the assessment of Zelapar's efficacy.\n",
      "- **Contributing Factors to Failure Probability:**\n",
      "  1. **Patient Selection:** The precise nature of the inclusion/exclusion criteria suggests a well-targeted patient population. Successful execution of these criteria is critical.\n",
      "  2. **Disease Variability:** Idiopathic PD expression varies significantly among patients, which can introduce variability in response to treatment.\n",
      "  3. **Adherence to Therapy:** Ensuring patients adhere to taking both Zelapar and levodopa consistently can be challenging and may affect trial outcomes.\n",
      "  4. **Previous Exposure and Tolerance:** Patients with prior exposure or high tolerance to elements of the treatment regimen might show reduced response.\n",
      "  5. **Drug Interactions:** Excluding patients on contraindicated medications is crucial to avoid adverse interactions, which could skew results.\n",
      "\n",
      "### Recommendations:\n",
      "- **Monitor for Adverse Events:** Regular monitoring for adverse effects, especially since Zelapar carries risks of hypertensive reactions with certain foods and other MAO interactions, is paramount.\n",
      "- **Standardized Assessment:** Ensure all patients are assessed using standardized protocols to evaluate their initial response to anti-Parkinsonian medications and subsequent response to Zelapar.\n",
      "- **Patient Engagement:** Strong communication strategies might improve adherence and provide more accurate data collection on drug efficacy.\n",
      "\n",
      "In conclusion, the probability of success in a clinical trial involving Zelapar and Parkinson's disease will heavily depend on precise execution of the study protocol and handling the inherent variability of Parkinson's disease. By mitigating potential risk factors identified above and focusing on the uniqueness of Zelapar as a formulation and its pharmacological interactions, the trial could be more successful.</solution>\n",
      "--------<function>efficiency_agent</function><result><function>get_SMILES</function><result>[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C</result>\n",
      "<function>retrieval_drugbank</function><result> \n",
      "    <drug name>mepatar</drug name>,\n",
      "    <drug description>A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.</drug description>,\n",
      "    <drug pharmacology indication>Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including <i>Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae</i> (respiratory infections), and <i>Diplococcus pneumoniae</i>.</drug pharmacology indication>,\n",
      "    <drug absorption>Readily absorbed following oral administration.</drug absorption>,\n",
      "    <drug volume-of-distribution>nan</drug volume-of-distribution>,\n",
      "    <drug metabolism>nan</drug metabolism>,\n",
      "    <drug route-of-elimination>nan</drug route-of-elimination>,\n",
      "    <drug toxicity>Adverse effects may include stomach or bowel upsets and rarely allergic reactions. Very rarely severe headache and vision problems may be signs of dangerous intracranial hypertenion.</drug toxicity>\n",
      "    </result>\n",
      "<function>retrieval_hetionet</function><result>NONE</result>\n",
      "Given the information about Zelapar (selegiline) and its application in the context of Parkinson's disease, here's an analysis that could help predict the probability of failure in your clinical trial:\n",
      "\n",
      "### Zelapar Overview:\n",
      "- **Active Ingredient:** Selegiline\n",
      "- **Primary Use:** Zelapar is primarily used as an adjunct therapy in the management of Parkinson's disease. It functions by selectively inhibiting the monoamine oxidase-B (MAO-B) enzyme, which is involved in the breakdown of dopamine in the brain, thereby increasing the level of dopamine available.\n",
      "- **Formulation:** Zelapar is unique as an orally disintegrating form of selegiline, allowing for better absorption and ease of administration.\n",
      "\n",
      "### Parkinson's Disease Context:\n",
      "- **Disease Characteristics:** Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, bradykinesia, rigidity, and non-motor symptoms.\n",
      "- **Current Therapies:** The standard treatment protocols often involve levodopa combined with carbidopa, MAO-B inhibitors like selegiline, dopamine agonists, and other adjunct therapies.\n",
      "\n",
      "### Clinical Trial Insights:\n",
      "- **Inclusion/Exclusion Criteria:** The trial's criteria are designed to filter out confounding variables that could interfere with the assessment of Zelapar's efficacy.\n",
      "- **Contributing Factors to Failure Probability:**\n",
      "  1. **Patient Selection:** The precise nature of the inclusion/exclusion criteria suggests a well-targeted patient population. Successful execution of these criteria is critical.\n",
      "  2. **Disease Variability:** Idiopathic PD expression varies significantly among patients, which can introduce variability in response to treatment.\n",
      "  3. **Adherence to Therapy:** Ensuring patients adhere to taking both Zelapar and levodopa consistently can be challenging and may affect trial outcomes.\n",
      "  4. **Previous Exposure and Tolerance:** Patients with prior exposure or high tolerance to elements of the treatment regimen might show reduced response.\n",
      "  5. **Drug Interactions:** Excluding patients on contraindicated medications is crucial to avoid adverse interactions, which could skew results.\n",
      "\n",
      "### Recommendations:\n",
      "- **Monitor for Adverse Events:** Regular monitoring for adverse effects, especially since Zelapar carries risks of hypertensive reactions with certain foods and other MAO interactions, is paramount.\n",
      "- **Standardized Assessment:** Ensure all patients are assessed using standardized protocols to evaluate their initial response to anti-Parkinsonian medications and subsequent response to Zelapar.\n",
      "- **Patient Engagement:** Strong communication strategies might improve adherence and provide more accurate data collection on drug efficacy.\n",
      "\n",
      "In conclusion, the probability of success in a clinical trial involving Zelapar and Parkinson's disease will heavily depend on precise execution of the study protocol and handling the inherent variability of Parkinson's disease. By mitigating potential risk factors identified above and focusing on the uniqueness of Zelapar as a formulation and its pharmacological interactions, the trial could be more successful.</result>\n",
      "<solution><function>efficiency_agent</function><result><function>get_SMILES</function><result>[H][C@@]12[C@@H](O)[C@@]3([H])C(C(=O)C4=C(C=CC=C4O)[C@@]3(C)O)=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C</result>\n",
      "<function>retrieval_drugbank</function><result> \n",
      "    <drug name>mepatar</drug name>,\n",
      "    <drug description>A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.</drug description>,\n",
      "    <drug pharmacology indication>Oxytetracycline is indicated for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including <i>Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae</i> (respiratory infections), and <i>Diplococcus pneumoniae</i>.</drug pharmacology indication>,\n",
      "    <drug absorption>Readily absorbed following oral administration.</drug absorption>,\n",
      "    <drug volume-of-distribution>nan</drug volume-of-distribution>,\n",
      "    <drug metabolism>nan</drug metabolism>,\n",
      "    <drug route-of-elimination>nan</drug route-of-elimination>,\n",
      "    <drug toxicity>Adverse effects may include stomach or bowel upsets and rarely allergic reactions. Very rarely severe headache and vision problems may be signs of dangerous intracranial hypertenion.</drug toxicity>\n",
      "    </result>\n",
      "<function>retrieval_hetionet</function><result>NONE</result>\n",
      "Given the information about Zelapar (selegiline) and its application in the context of Parkinson's disease, here's an analysis that could help predict the probability of failure in your clinical trial:\n",
      "\n",
      "### Zelapar Overview:\n",
      "- **Active Ingredient:** Selegiline\n",
      "- **Primary Use:** Zelapar is primarily used as an adjunct therapy in the management of Parkinson's disease. It functions by selectively inhibiting the monoamine oxidase-B (MAO-B) enzyme, which is involved in the breakdown of dopamine in the brain, thereby increasing the level of dopamine available.\n",
      "- **Formulation:** Zelapar is unique as an orally disintegrating form of selegiline, allowing for better absorption and ease of administration.\n",
      "\n",
      "### Parkinson's Disease Context:\n",
      "- **Disease Characteristics:** Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as tremor, bradykinesia, rigidity, and non-motor symptoms.\n",
      "- **Current Therapies:** The standard treatment protocols often involve levodopa combined with carbidopa, MAO-B inhibitors like selegiline, dopamine agonists, and other adjunct therapies.\n",
      "\n",
      "### Clinical Trial Insights:\n",
      "- **Inclusion/Exclusion Criteria:** The trial's criteria are designed to filter out confounding variables that could interfere with the assessment of Zelapar's efficacy.\n",
      "- **Contributing Factors to Failure Probability:**\n",
      "  1. **Patient Selection:** The precise nature of the inclusion/exclusion criteria suggests a well-targeted patient population. Successful execution of these criteria is critical.\n",
      "  2. **Disease Variability:** Idiopathic PD expression varies significantly among patients, which can introduce variability in response to treatment.\n",
      "  3. **Adherence to Therapy:** Ensuring patients adhere to taking both Zelapar and levodopa consistently can be challenging and may affect trial outcomes.\n",
      "  4. **Previous Exposure and Tolerance:** Patients with prior exposure or high tolerance to elements of the treatment regimen might show reduced response.\n",
      "  5. **Drug Interactions:** Excluding patients on contraindicated medications is crucial to avoid adverse interactions, which could skew results.\n",
      "\n",
      "### Recommendations:\n",
      "- **Monitor for Adverse Events:** Regular monitoring for adverse effects, especially since Zelapar carries risks of hypertensive reactions with certain foods and other MAO interactions, is paramount.\n",
      "- **Standardized Assessment:** Ensure all patients are assessed using standardized protocols to evaluate their initial response to anti-Parkinsonian medications and subsequent response to Zelapar.\n",
      "- **Patient Engagement:** Strong communication strategies might improve adherence and provide more accurate data collection on drug efficacy.\n",
      "\n",
      "In conclusion, the probability of success in a clinical trial involving Zelapar and Parkinson's disease will heavily depend on precise execution of the study protocol and handling the inherent variability of Parkinson's disease. By mitigating potential risk factors identified above and focusing on the uniqueness of Zelapar as a formulation and its pharmacological interactions, the trial could be more successful.</result></solution>\n",
      "Solving...\n",
      "--------[Action] Function calling...\n",
      "--------\n",
      "--------Enrollment Agent...\n",
      "--------Planing...\n",
      "--------[Thought] Least to Most Reasoning: Decompose the original problem\n",
      "----------------[Action] Function calling...\n",
      "--------<solution><function>get_enrollment_difficulty</function><result>The enrollment difficulty of the clinical trial based on the eligibility criteria is 0.24709999561309814. Higher values indicate greater difficulty in enrollment.</result></solution\n",
      "--------<function>enrollment_agent</function><result><function>get_enrollment_difficulty</function><result>The enrollment difficulty of the clinical trial based on the eligibility criteria is 0.24709999561309814. Higher values indicate greater difficulty in enrollment.</result></result>\n",
      "<solution><function>enrollment_agent</function><result><function>get_enrollment_difficulty</function><result>The enrollment difficulty of the clinical trial based on the eligibility criteria is 0.24709999561309814. Higher values indicate greater difficulty in enrollment.</result></result></solution>\n",
      "Thinking...\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "d:\\projects\\personal-researches\\clinical-agent\\algo\\agents\\tools\\enrollment\\__init__.py:136: FutureWarning: You are using `torch.load` with `weights_only=False` (the current default value), which uses the default pickle module implicitly. It is possible to construct malicious pickle data which will execute arbitrary code during unpickling (See https://github.com/pytorch/pytorch/blob/main/SECURITY.md#untrusted-models for more details). In a future release, the default value for `weights_only` will be flipped to `True`. This limits the functions that could be executed during unpickling. Arbitrary objects will no longer be allowed to be loaded via this mode unless they are explicitly allowlisted by the user via `torch.serialization.add_safe_globals`. We recommend you start setting `weights_only=True` for any use case where you don't have full control of the loaded file. Please open an issue on GitHub for any issues related to this experimental feature.\n",
      "  torch.load(f\"{current_file_path}/data/enrollment_model.pt\")\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[Action] Requesting the final result from the Reasoning Agent...\n",
      "To solve the user's problem of predicting the probability of failure for the clinical trial involving Zelapar for Parkinson's disease, we can analyze the data and insights derived from the subproblem results.\n",
      "\n",
      "**Analysis:**\n",
      "\n",
      "1. **Historical Failure Rates**:\n",
      "   - Zelapar's historical failure rate in clinical trials is 0.0, indicating it has performed exceptionally well historically.\n",
      "   - Parkinson's disease, however, has a moderate historical failure rate at 0.3566, reflecting the complexity and variability in its clinical management.\n",
      "\n",
      "2. **Trial Design and Eligibility Criteria**:\n",
      "   - Your trial's inclusion and exclusion criteria are specifically detailed and targeted, aiming to select a patient population that is likely to benefit most from Zelapar. This should theoretically reduce external variability and focus results on the drug's efficacy and safety.\n",
      "\n",
      "3. **Handling of Parkinson's Disease Variability**:\n",
      "   - By establishing stringent criteria for inclusion (like confirmed idiopathic Parkinson's with specific symptoms and current medication), you are likely to reduce confounding factors due to misdiagnosis or variant prognostic factors.\n",
      "   - Excluding individuals with drug contraindications and severe comorbid conditions should enhance patient safety and trial data integrity.\n",
      "\n",
      "4. **Enrollment and Operational Execution**:\n",
      "   - The difficulty of enrollment calculated is relatively low at 0.2471, suggesting that finding suitable candidates for your trial, given the criteria, should not be excessively challenging. This assists in timely and efficient trial execution.\n",
      "\n",
      "**Conclusion:**\n",
      "\n",
      "Given the rigorous design of the inclusion and exclusion criteria, coupled with Zelaparâ€™s historically excellent performance and a highly focused trial scenario:\n",
      "- The probability of failure is mainly leveraged by the disorder's moderate historical variability and response to treatment.\n",
      "- The precision in trial design and operational planning offer substantial mitigation against this inherent risk.\n",
      "\n",
      "By synthesizing these findings:\n",
      "- Zelapar's effective history gives significant confidence in its potential success in this trial context.\n",
      "- Parkinson's disease's inherent complexity and response variability represent the main risk drivers. However, this risk appears well-managed through the trialâ€™s design.\n",
      "\n",
      "**Final Prediction**:\n",
      "\n",
      "Considering the high efficacy and management projected by the trial design, the balanced prediction for the probability of failure, factoring in Parkinson's disease's moderate historical failure rate, would be considerably lower than this rate due to Zelaparâ€™s strong historical performance and solid trial design.\n",
      "\n",
      "Therefore, the predicted probability of failure for this clinical trial is:\n",
      "\n",
      "<final_result>0.15</final_result>\n",
      "\n",
      "**Reasoning**:\n",
      "This prediction balances the low failure potential of Zelapar against the moderate inherent clinical variability and treatment response difficulties associated with Parkinson's disease, adjusted by strong trial design and patient management strategies.\n",
      "\n",
      "======================    END   ================\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆ| 1/1 [01:04<00:00, 64.16s/it]\n"
     ]
    }
   ],
   "source": [
    "subproblems_solved = []\n",
    "final_results = []\n",
    "labels = []\n",
    "nctid_idxs = []\n",
    "random_idxs =[]\n",
    "\n",
    "\n",
    "random_seed = 47\n",
    "random.seed(random_seed)\n",
    "for i in tqdm(range(30)):\n",
    "    random_idx = random.randint(0, trial_df.shape[0]-1)\n",
    "    LOGGER.log_with_depth(f\"Random Index: {random_idx}\", depth=0)\n",
    "\n",
    "    trial_row = trial_df.iloc[random_idx]\n",
    "\n",
    "    try:\n",
    "        nctid = trial_row['nctid']\n",
    "        criteria = trial_row['criteria']\n",
    "        drugs = trial_row['drugs']\n",
    "        diseases = trial_row['diseases']\n",
    "        label = trial_row['label']\n",
    "\n",
    "        LOGGER.log_with_depth(f\"NCT ID: {nctid}, Label: {1-label}\\n\", depth=0)\n",
    "\n",
    "        user_problem = f'''\n",
    "        #My problem#: <problem>I have designed a clinical trial and hope you can help me predict the probability of failure for this clinical trial.</problem>\n",
    "        #drugs#: <drug>{drugs}</drug>\n",
    "        #diseases#: <disease>{diseases}</disease>\n",
    "        #criteria#: <criteria>{criteria}</criteria>\n",
    "        '''\n",
    "\n",
    "        subproblem_solve, final_result_str = solve_problem(user_problem)\n",
    "\n",
    "        subproblems_solved.append(subproblem_solve)\n",
    "        final_results.append(final_result_str)\n",
    "        labels.append(label)\n",
    "        nctid_idxs.append(nctid)\n",
    "        random_idxs.append(random_idx)\n",
    "\n",
    "        LOGGER.log_with_depth(\"\\n\\n\\n\\n\\n\\n\\n\\n\", depth=0)\n",
    "\n",
    "    except Exception as e:\n",
    "        LOGGER.log_with_depth(f\"Error: {e}\", depth=0)\n",
    "        continue"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sample Indexes: [90]\n",
      "NCT ID Indexes: ['NCT00640159']\n",
      "Length of y_true: 1\n",
      "Length of positive label: 0\n",
      "y_true: [np.int64(0)]\n",
      "y_pred_probs: [0.15]\n",
      "\n",
      "Accuracy: 1.0\n"
     ]
    }
   ],
   "source": [
    "def get_final_result(final_str):\n",
    "    try:\n",
    "        likelihood = re.search(r'<final_result>(.*?)</final_result>', final_str).group(1)\n",
    "        likelihood = float(re.findall(r\"\\d+(?:\\.\\d+)?\", likelihood)[0])\n",
    "    except Exception as e:\n",
    "        return 0.5\n",
    "    \n",
    "    # Percentage\n",
    "    if likelihood > 1:\n",
    "        likelihood = likelihood / 100\n",
    "    \n",
    "    if likelihood < 0 or likelihood > 1:\n",
    "        likelihood = 0.5\n",
    "\n",
    "    return likelihood\n",
    "\n",
    "# Success to failure\n",
    "y_true = [1-label for label in labels]\n",
    "\n",
    "print(f\"Sample Indexes: {random_idxs}\")\n",
    "print(f\"NCT ID Indexes: {nctid_idxs}\")\n",
    "\n",
    "print(f\"Length of y_true: {len(y_true)}\")\n",
    "print(f\"Length of positive label: {len([label for label in y_true if label == 1])}\")\n",
    "print(f\"y_true: {y_true}\")\n",
    "\n",
    "y_pred_probs = [get_final_result(result) for result in final_results]\n",
    "\n",
    "print(f\"y_pred_probs: {y_pred_probs}\\n\")\n",
    "\n",
    "# Convert predicted probabilities to binary predictions\n",
    "threshold = 0.5\n",
    "y_pred = [1 if prob >= threshold else 0 for prob in y_pred_probs]\n",
    "\n",
    "# Calculate metrics\n",
    "print(\"Accuracy:\", accuracy_score(y_true, y_pred))\n",
    "print(\"ROC-AUC Score:\", roc_auc_score(y_true, y_pred_probs))\n",
    "\n",
    "# Calculating PR AUC\n",
    "precision, recall, _ = precision_recall_curve(y_true, y_pred_probs)\n",
    "pr_auc = auc(recall, precision)\n",
    "print(\"PR AUC:\", pr_auc)\n",
    "\n",
    "print(\"Precision:\", precision_score(y_true, y_pred))\n",
    "print(\"Recall:\", recall_score(y_true, y_pred))\n",
    "print(\"F1 Score:\", f1_score(y_true, y_pred))\n",
    "print(\"Log Loss:\", log_loss(y_true, y_pred_probs))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "clinical-agent",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
